But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
ApexOnco Front Page
Recent articles
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
But BeOne canned its alcestobart deal in May.
